Last reviewed · How we verify
Human Umbilical Cord derived MSCs
At a glance
| Generic name | Human Umbilical Cord derived MSCs |
|---|---|
| Also known as | Allogeneic stem cells derived from umbilical cord |
| Sponsor | CytoMed & Beike |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Phase 3 Pivotal Trial Comparing CARTISTEM® and Surgical Comparator for Knee Cartilage Lesions and Osteoarthritis (PHASE3)
- Umbilical Cord-derived Mesenchymal Stem Cell Infusion in the Management of Adult Liver Cirrhosis (PHASE1)
- Handheld MPI Imaging to Track Stem Cells in Osteoarthritis (EARLY_PHASE1)
- Clinical Research on Stem Cell Therapy for Parkinson's Disease (PHASE1)
- Repair of Acute Respiratory Distress Syndrome by Stromal Cell Administration (REALIST) (PHASE1, PHASE2)
- Allogeneic Umbilical Cord Mesenchymal Stromal Cells for the Treatment of Chronic Antibody-Mediated Rejection in Kidney Transplantation (PHASE2)
- Study of Human Umbilical Cord-derived Mesenchymal Stem Cells for Treatment of Refractory Immune Thrombocytopenia (NA)
- Evaluation Safety and Explore Efficacy Long-term Follow-up Study on Subjects Receiving SMUP-IA-01 or Active Control (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Human Umbilical Cord derived MSCs CI brief — competitive landscape report
- Human Umbilical Cord derived MSCs updates RSS · CI watch RSS
- CytoMed & Beike portfolio CI